Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

Autor: Epperla N; Division of Hematology, The Ohio State University, Columbus, OH., Zhao Q; Division of Hematology, The Ohio State University, Columbus, OH., Chowdhury SM; Division of Hematology, The Ohio State University, Columbus, OH., Shea L; Division of Hematology, Washington University, St. Louis, MO., Moyo TK; Levine Cancer Center, Atrium Health, Charlotte, NC., Reddy N; Vanderbilt University Medical Center, Nashville, TN., Sheets J; Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC., Weiner DM; Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Geethakumari PR; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Kandarpa M; Division of Hematology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Bruno XJ; Division of Hematology and Oncology, University of Vermont, Burlington, VT., Thomas C; Division of Hematology, Thomas Jefferson University, Philadelphia, PA., Churnetski MC; Winship Cancer Institute, Emory University Medical Center, Atlanta, GA., Hsu A; Division of Hematology, Brown University, Providence, RI., Zurbriggen L; Division of Hematology, University of Wisconsin, Madison, WI., Tan XC; Cancer Institute of New Jersey, New Brunswick, NJ., Lindsey K; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC., Maakaron J; Division of Hematology, University of Minnesota, Minneapolis, MN., Caimi PF; University Hospitals Seidman Cancer Center, Cleveland, OH., Torka P; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY., Bello C; Division of Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Ayyappan S; Division of Hematology and Oncology, University of Iowa, Iowa City, IA., Oh TS; Division of Hematology, Northwestern University, Chicago, IL., Karmali R; Division of Hematology, Northwestern University, Chicago, IL., Kim SH; Division of Hematology and Oncology, Rush University, Chicago, IL., Kress A; Division of Hematology, Yale University, New Haven, CT., Kothari S; Division of Hematology, Yale University, New Haven, CT., Sawalha Y; Division of Hematology, The Ohio State University, Columbus, OH., Christian B; Division of Hematology, The Ohio State University, Columbus, OH., David KA; Cancer Institute of New Jersey, New Brunswick, NJ., Greenwell IB; Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC., Janakiram M; Division of Hematology, University of Minnesota, Minneapolis, MN., Kenkre VP; Division of Hematology, University of Wisconsin, Madison, WI., Olszewski AJ; Division of Hematology, Brown University, Providence, RI., Cohen JB; Winship Cancer Institute, Emory University Medical Center, Atlanta, GA., Palmisiano N; Division of Hematology, Thomas Jefferson University, Philadelphia, PA., Umyarova E; Division of Hematology and Oncology, University of Vermont, Burlington, VT., Wilcox RA; Division of Hematology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Alderuccio JP; Division of Hematology, University of Miami, Miami, FL., Barta SK; Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Grover NS; Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC., Ghosh N; Levine Cancer Center, Atrium Health, Charlotte, NC., Bartlett NL; Division of Hematology, Washington University, St. Louis, MO., Herrera AF; Division of Hematology, City of Hope, Duarte, CA., Shouse G; Division of Hematology, City of Hope, Duarte, CA.
Jazyk: angličtina
Zdroj: Blood advances [Blood Adv] 2023 Jan 10; Vol. 7 (1), pp. 88-91.
DOI: 10.1182/bloodadvances.2022008634
Databáze: MEDLINE